Wall Street Zen upgraded shares of Solana (NASDAQ:HSDT – Free Report) from a sell rating to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.
A number of other research firms have also recently commented on HSDT. Weiss Ratings reissued a “sell (e+)” rating on shares of Solana in a report on Thursday, October 15th. B. Riley Financial reduced their price target on shares of Solana from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $3.50.
Read Our Latest Report on Solana
Solana Stock Down 8.5%
Solana (NASDAQ:HSDT – Get Free Report) last announced its quarterly earnings data on Wednesday, November 11th. The company reported $1.17 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $1.18. The business had revenue of $3.36 million during the quarter, compared to the consensus estimate of $2.85 million. Solana had a return on equity of 134.60% and a net margin of 2,040.43%. On average, research analysts predict that Solana will post -0.25 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Solana stock. Saba Capital Management L.P. bought a new stake in Solana Company (NASDAQ:HSDT – Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 65,210 shares of the company’s stock, valued at approximately $113,000. Saba Capital Management L.P. owned about 0.12% of Solana at the end of the most recent reporting period. Institutional investors and hedge funds own 18.63% of the company’s stock.
Solana Company Profile
Solana Company (NASDAQ: HSDT) is a publicly traded company focused on a digital-asset treasury strategy centered on SOL, the native token of the Solana blockchain. It is a corporate holder of Solana-related digital assets, rather than the operator of the Solana network. The company was formerly Helius Medical Technologies, a medical technology business that developed the Portable Neuromodulation Stimulator (PoNS), a device designed to support rehabilitation for people with certain neurological conditions.
Recommended Stories
- Five stocks we like better than Solana
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Solana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solana and related companies with MarketBeat.com's FREE daily email newsletter.
